Rigel Pharmaceuticals Inc reports results for the quarter ended in March - Earnings Summary

Rigel Pharmaceuticals

07/05/2024 22:23

* Rigel Pharmaceuticals Inc  RIGL.OQ  reported a quarterly
adjusted loss of 5 cents​​ per share for the quarter ended in
March, higher than the same quarter last year, when the company
reported EPS of -8 cents.  The mean expectation of six analysts
for the quarter was for a loss of 3 cents per share. Wall Street
expected results to range from -4 cents to -1 cents per share.
    * Revenue rose 13.3% to $29.53 million from a year ago;
analysts
expected $31.28 million. 
    * Rigel Pharmaceuticals Inc's reported EPS for the quarter
was a
loss of 5 cents​.
    * The company reported a quarterly loss of $8.25 million.
    * Rigel Pharmaceuticals Inc shares had fallen by 17.6% this
quarter and lost 15.9% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 28.8%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," 4
"hold" and no "sell" or "strong sell." 
    * Wall Street's median 12-month price target for Rigel
Pharmaceuticals Inc is $2.50 

This summary was machine generated from LSEG data May 7 at 09:22
p.m. UTC. ​All figures in US dollars unless otherwise stated.
(For questions concerning the data in this report, contact
Estimates.Support@lseg.com. For any other questions or feedback,
contact RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Mar. 31 2024      -0.03          -0.05          Missed
 Dec. 31 2023      -0.03          0.00           Beat
 Sep. 30 2023      -0.07          -0.03          Beat
 Jun. 30 2023      -0.08          -0.04          Beat